請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/64458
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 沈麗娟 | |
dc.contributor.author | Chen-Fang Lin | en |
dc.contributor.author | 林珍芳 | zh_TW |
dc.date.accessioned | 2021-06-16T17:48:22Z | - |
dc.date.available | 2017-09-19 | |
dc.date.copyright | 2012-09-19 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-08-14 | |
dc.identifier.citation | 1. Buck CJ. 2001 ICD-9-CM, . 1st edition ed: W B Saunders Co; 2001.
2. 2010 Statistics of Causes of Death 2010. (Accessed 2012/5/5, 2012, at http://www.doh.gov.tw/CHT2006/DM/DM2_2.aspx?now_fod_list_no=11962&class_no=440&level_no=4.) 3. Kushner FG, Hand M, Smith SC, Jr., et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009;120:2271-306. 4. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002;106:1893-900. 5. Margulis AV, Choudhry NK, Dormuth CR, Schneeweiss S. Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004. Pharmacoepidemiol Drug Saf 2011;20:1088-97. 6. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231-43. 7. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. 8. Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-7. 9. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998;97:2202-12. 10. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-8. 11. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78. 12. Avezum A, Makdisse M, Spencer F, et al. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2005;149:67-73. 13. Schoenenberger AW, Radovanovic D, Stauffer JC, et al. Age-related differences in the use of guideline-recommended medical and interventional therapies for acute coronary syndromes: a cohort study. J Am Geriatr Soc 2008;56:510-6. 14. Yan RT, Yan AT, Tan M, et al. Age-related differences in the management and outcome of patients with acute coronary syndromes. Am Heart J 2006;151:352-9. 15. Rosengren A, Wallentin L, Simoons M, et al. Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey. Eur Heart J 2006;27:789-95. 16. Barchielli A, Buiatti E, Balzi D, et al. Age-related changes in treatment strategies for acute myocardial infarction: a population-based study. J Am Geriatr Soc 2004;52:1355-60. 17. Rathore SS, Mehta RH, Wang Y, Radford MJ, Krumholz HM. Effects of age on the quality of care provided to older patients with acute myocardial infarction. Am J Med 2003;114:307-15. 18. Mehta RH, Rathore SS, Radford MJ, Wang Y, Krumholz HM. Acute myocardial infarction in the elderly: differences by age. J Am Coll Cardiol 2001;38:736-41. 19. Brogan GX, Jr., Peterson ED, Mulgund J, et al. Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes. Diabetes Care 2006;29:9-14. 20. Bugiardini R, Yan AT, Yan RT, et al. Factors influencing underutilization of evidence-based therapies in women. Eur Heart J 2011;32:1337-44. 21. Hasdai D, Haim M, Behar S, Boyko V, Battler A. Acute coronary syndromes in patients with prior cerebrovascular events: lessons from the Euro-Heart Survey of Acute Coronary Syndromes. Am Heart J 2003;146:832-8. 22. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003;42:201-8. 23. World Alzheimer Report: The Global Economic Impact of Dementia. 2010. 24. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-7. 25. Kimata T, Hirakawa Y, Uemura K, Kuzuya M. Absence of outcome difference in elderly patients with and without dementia after acute myocardial infarction. Int Heart J 2008;49:533-43. 26. Hirakawa Y, Masuda Y, Kuzuya M, Iguchi A, Uemura K. [Differences in cardiac management and in-hospital mortality between elderly patients with and without dementia after acute myocardial infarction: findings from TAMIS data]. Nippon Ronen Igakkai Zasshi 2007;44:606-10. 27. Cordero A, Morillas P, Bertomeu-Gonzalez V, et al. Pathological ankle-brachial index is equivalent of advanced age in acute coronary syndromes. Eur J Clin Invest 2011. 28. Sloan FA, Trogdon JG, Curtis LH, Schulman KA. The effect of dementia on outcomes and process of care for Medicare beneficiaries admitted with acute myocardial infarction. J Am Geriatr Soc 2004;52:173-81. 29. Ballantyne CM. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol 1998;82:3Q-12Q. 30. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48:438-45. 31. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Arterioscler Thromb Vasc Biol 2004;24:e149-61. 32. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005;46:1411-6. 33. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): A Multicenter Survey to Evaluate the Percentages of Dyslipidemic Patients Receiving Lipid-Lowering Therapy and Achieving Low-Density Lipoprotein Cholesterol Goals. Arch Intern Med 2000;160:459-67. 34. Hyre AD, Muntner P, Menke A, Raggi P, He J. Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults. Ann Epidemiol 2007;17:548-55. 35. Avellone G, Di Garbo V, Guarnotta V, et al. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia. Int Angiol 2010;29:514-24. 36. Waters DD, Brotons C, Chiang CW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009;120:28-34. 37. Davis HR, Jr., Zhu LJ, Hoos LM, et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 2004;279:33586-92. 38. Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943-8. 39. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005;149:464-73. 40. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005;80:587-95. 41. Bays HE, Ose L, Fraser N, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004;26:1758-73. 42. Kosoglou T, Meyer I, Veltri EP, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002;54:309-19. 43. Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91. 44. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487-94. 45. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107:2409-15. 46. Sager PT, Capece R, Lipka L, et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 2005;179:361-7. 47. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007;115:459-67. 48. Meaney A, Ceballos G, Asbun J, et al. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol 2009;49:838-47. 49. Kesaniemi A. Cholesterol absorption inhibitors in the treatment of hyperlipidemia: clinical outcomes in large clinical trials. Fundam Clin Pharmacol 2007;21 Suppl 2:29-30. 50. Steinhubl SR, Berger PB, Mann JT, 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20. 51. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008;118:1894-909. 52. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891-6. 53. Nguyen T, Frishman WH, Nawarskas J, Lerner RG. Variability of response to clopidogrel: possible mechanisms and clinical implications. Cardiol Rev 2006;14:136-42. 54. Hagihara K, Kazui M, Kurihara A, et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos 2009;37:2145-52. 55. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010;38:92-9. 56. Fontana P, Hulot JS, De Moerloose P, Gaussem P. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J Thromb Haemost 2007;5:2153-5. 57. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004;109:166-71. 58. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62. 59. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. N Engl J Med 2009;360:363-75. 60. (FDA) TUSFaDA. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. In: The U.S. Food and Drug Administration (FDA); 2010. 61. Aronow HD, Steinhubl SR, Brennan DM, Berger PB, Topol EJ. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2009;157:369-74. 62. Schreiner GC, Laine L, Murphy SA, Cannon CP. Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed. Crit Pathw Cardiol 2007;6:169-72. 63. Khalique SC, Cheng-Lai A. Drug interaction between clopidogrel and proton pump inhibitors. Cardiol Rev 2009;17:198-200. 64. Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821-7. 65. Liu TJ, Jackevicius CA. Drug interaction between clopidogrel and proton pump inhibitors. Pharmacotherapy 2010;30:275-89. 66. Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med 2010;170:704-10. 67. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44. 68. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-8. 69. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009;120:2322-9. 70. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010;152:337-45. 71. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009. 72. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008;48:475-84. 73. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-60. 74. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157:148 e1-5. 75. Yun KH, Rhee SJ, Park HY, et al. Effects of omeprazole on the antiplatelet activity of clopidogrel. Int Heart J 2010;51:13-6. 76. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999;9:539-49. 77. Kaneko A, Lum JK, Yaviong L, et al. High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. Pharmacogenetics 1999;9:581-90. 78. Mo-li Zheng S-tZ. Comprehensive Coding Guidelines in ICD-9-CM: Taiwan Medical and Health Information Management Association; 2007. 79. Wu CS, Ting TT, Wang SC, Chang IS, Lin KM. Effect of benzodiazepine discontinuation on dementia risk. Am J Geriatr Psychiatry 2011;19:151-9. 80. Austin PC. Primer on statistical interpretation or methods report card on propensity-score matching in the cardiology literature from 2004 to 2006: a systematic review. Circ Cardiovasc Qual Outcomes 2008;1:62-7. 81. D'Agostino RB, Jr. Propensity scores in cardiovascular research. Circulation 2007;115:2340-3. 82. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-63. 83. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2010. 84. Wimo A, Winblad B, Jonsson L. The worldwide societal costs of dementia: Estimates for 2009. Alzheimers Dement 2010;6:98-103. 85. David W. Hosmer SL, Susanne May. Applied survival analysis: Regression modeling of time to event data. Second edition ed. New York, USA: Wiley-Interscience; 2008. 86. Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006;98:253-9. 87. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9. 88. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57. 89. Lee HY, Cooke CE, Robertson TA. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm 2008;14:271-80. 90. Hsuan C-F, Lee T-L, Chang H-L, Tseng W-K, Wu C-C. A Retrospective Study of Statin Use and Its Effectiveness in Taiwanese. Acta Cardiologica Sinica 2009;25:25. 91. Soiza RL, Leslie SJ, Harrild K, Peden NR, Hargreaves AD. Age-dependent differences in presentation, risk factor profile, and outcome of suspected acute coronary syndrome. J Am Geriatr Soc 2005;53:1961-5. 92. Parsons C, Hughes CM, Passmore AP, Lapane KL. Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying? Drugs Aging 2010;27:435-49. 93. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56. 94. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92. 95. Krumholz HM, Anderson JL, Bachelder BL, et al. ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to develop performance measures for ST-elevation and non-ST-elevation myocardial infarction): developed in collaboration with the American Academy of Family Physicians and the American College of Emergency Physicians: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine. Circulation 2008;118:2596-648. 96. Ray KK, Cannon CP. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? Am J Cardiol 2005;96:54F-60F. 97. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-22. 98. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421. 99. Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004;148:447-55. 100. Rotella CM, Zaninelli A, Le Grazie C, Hanson ME, Gensini GF. Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes. Lipids Health Dis 2010;9:80. 101. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008;52:1038-9; author reply 9. 102. Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother 2009;43:1266-74. 103. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 2011;89:65-74. 104. Fontes-Carvalho R, Albuquerque A, Araujo C, Pimentel-Nunes P, Ribeiro VG. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. Eur J Gastroenterol Hepatol 2011;23:396-404. 105. Ogilvie BW, Yerino P, Kazmi F, et al. The Proton Pump Inhibitor, Omeprazole, but not Lansoprazole or Pantoprazole, is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel. Drug Metab Dispos 2011. 106. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-75. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/64458 | - |
dc.description.abstract | 研究背景
臨床研究建議使用aspirin, beta-blockers, angiotensin-converting enzyme inhibitor (ACEI) 或 angiotensin receptor blocker (ARB), statins 以及clopidogrel來治療急性冠心症病人,因為已有許多研究證實這些藥物治療可以降低病人急性冠心症致疾病率以及死亡率。但許多的研究持續發現這些藥物在急性冠心症病人的使用率並未達到理想的標準。本論文將進一步研究影響藥物使用率的病人特質或共病,以提出改善藥物使用率的措施。近年來,老年人以及老年癡呆症的病人數日益增加。對於老年以及老年癡呆症對急性冠心症病人藥物治療的影響,所知有限。合併ezetimibe 以及statins在治療急性冠心症病人的臨床效果如降低心血管風險的再發率,尚未被證實,且目前的臨床研究尚未有定論。另外,對急性冠心症病人有實證益處的藥物,其效果可能會受某些併用藥物的影響。急性冠心症病人合併使用clopidogrel 以及氫離子幫浦抑制劑,對於其心血管風險的再發率的影響,目前的臨床研究尚未有定論。也尚未有研究特別針對5種各別不同的氫離子幫浦抑制劑與clopidogrel併用,對心血管風險再發率的影響,做進一步的探討。 研究目的 基本的分析研究主要分四個部分。第一個研究目的是,急性冠心症病人使用藥物治療的現況。第二個研究目的是,老年癡呆症對於不同年齡層的急性冠心症病人藥物治療的影響。第三個研究目的是,合併使用ezetimibe 以及statins對於急性冠心症病人的臨床效果。第四個研究目的是,合併使用clopidogrel 以及氫離子幫浦抑制劑,對於急性冠心症病人心血管風險再發率的影響。 研究方法 基本分析之方法,主要分四個部分。 第一個研究,從健保資料庫中根據主要的出院診斷,在2006年1月1日到2007年12月31日因急性冠心症而住院的病人有111,347人,經排除在2005年因急性冠心症而住院,年齡小於18歲以及出院日期無法得知之病人,原始的急性冠心症病人共有87,321人。進一步將原始的急性冠心症病人分為以: 在原始的急性冠心症世代87,321人中,其中有1835位老年癡呆症病人,經過1比2的年齡、性別以及醫院別配對後有3670個非老年癡呆症病人。此研究主題為橫斷面研究設計。我們對於分佈於4個年齡層(≤65, 66-75, 76-85, >85)的有無老年癡呆症病人,使用藥物治療以及介入性治療進行比較。並使用多變項的羅吉式迴歸來進行,老年癡呆症對於急性冠心症病人藥物治療以及介入性治療的分析。 在原始的急性冠心症世代87,321人中,有使用statin的病人共有37,753人,合併使用statin以及ezetimibe的病人有1001人。進一步用傾向分數進行1:1配對得到共2002位病人。此研究主題為回溯性世代研究設計。並使用多變項的Cox proportional hazards羅吉式迴歸來進行分析。 在原始的急性冠心症世代87,321人中,有使用clopidogrel的病人共有37,099人,進一步用傾向分數進行1:1配對,得到clopidogrel單獨或合併使用氫離子幫浦抑制劑各組5173人。此研究主題為回溯性世代研究設計。並使用多變項的Cox proportional hazards羅吉式迴歸來進行分析。 研究結果 基本分析之結果,主要分四個部分。 第一個研究,整體來說,急性冠心症病人使用藥物治療的比例,隨著年齡的增加而下降,以aspirin為例,在最年輕組的使用比例為43.2%,最年長組的使用比例為24.8%。男性病人使用藥物治療的比例較女性病人高,以aspirin為例,在男性的使用比例為45.0%,在女性的使用比例為31.9%。 第二個研究,整體來說,老年癡呆症病人有相對較低 27% 機率接受介入性治療(調整後勝算比0.73, 95% 信賴區間0.63-0.83)以及相對較低 22% 機率接受藥物治療(調整後勝算比0.78, 95% 信賴區間0.68-0.89)。急性冠心症病人的藥物治療使用與介入性治療皆隨著病人年齡的增加而下降,如果病人有老年癡呆症,會更降低兩者的使用率。 第三個研究,在原始的世代研究族群中,statins 合併使用ezetimibe組的急性冠心症再發率為13.4 每100個人年 (共268事件),相對於單獨statins組的急性冠心症再發率為22.6 每100個人年 (共12,724 events事件),(風險比, 0.69; 95% 信賴區間, 0.62-0.78). 在經配對後的世代研究族群中,statins 合併使用ezetimibe組的急性冠心症再發率為13.4 每100個人年,相對於單獨使用statins組的急性冠心症再發率為20.0 每100個人年,(風險比, 0.62; 95% 信賴區間, 0.53-0.73)。在經配對後的世代研究族群中,相對於單獨使用statins組,因進行冠狀動脈氣球擴張術未加或加支架以及血管再形成術而再入院, statins 合併使用ezetimibe組,風險比分別為 0.61 (95% 信賴區間, 0.50-0.75), 0.62 (95% 信賴區間, 0.48-0.81)以及0.62 (95% 信賴區間, 0.51- 0.76)。 第四個研究,在經傾向分數配對的世代中,相對於單獨使用clopidogrel組,合併使用clopidogrel以及氫離子幫浦抑制劑組的調整後風險比為1.05 (95% 信賴區間, 0.97-1.14, p值為0.21)。在所有的氫離子幫浦抑制劑中,只有omeprazole與clopidogrel併用會增加因急性冠心症再入院風險 (調整後風險比1.23; 95% 信賴區間, 1.07-1.41, p值為0.004). 合併其它氫離子幫浦抑制劑如esomeprazole, pantoprazole, rabeprazole 以及lansoprazole,沒有發現統計上有意義的相關性。 結論 由我們的研究發現,在台灣急性冠心症病人使用預防再次發病治療藥物的比例低於45%,接受介入性治療的比例低於42%。同時,使用預防再次發病治療藥物的比例,也隨著年齡的增加或合併有老年癡呆症而下降。此外,急性冠心症病人合併使用statins以及ezetimibe相對於單獨使用statins,有較低的,因急性冠心症、冠狀動脈氣球擴張術未加或加支架,以及血管再形成術而再入院,有較低的風險比。然而,對於合併使用ezetimibe以及statins的臨床效果之機轉,還有待未來研究的進一步分析。合併使用clopidogrel以及氫離子幫浦抑制劑,對於增加因急性冠心症再入院風險並無統計上意義。但clopidogrel合併使用omeprazole,在增加因急性冠心症再入院風險有統計上的意義。對於合併使用clopidogrel以及omeprazole而增加因急性冠心症再入院風險之機轉,還有待未來研究的進一步分析。 | zh_TW |
dc.description.abstract | Background
Clinical studies have supported the beneficial effects of medical therapies (such as aspirin, beta-blockers, angiotensin-converting enzyme inhibitor (ACEI) orangiotensin receptor blocker (ARB), statins and clopidogrel) for reducing the risks of morbidity and mortality in acute coronary syndrome (ACS) patients. Studies have consistently shown that medical therapies such as aspirin, beta-blockers, ACEI or ARB, statins, and clopidogrel remained underused in the management of patients with ACS. In order to find out the strategies for improvement in utilization of the medications, the factors such as patient characteristics and comorbidity associated with the utilization of the medications are required for further investigation. The prevalence of elderly and dementia patients are growing considerately in the recent years. Little is known about how aging and dementia affects therapy after discharge for ACS. Some surrogate endpoints were adopted to investigate the effectiveness of ezetimibe in addition to statins in reducing the risk of cardiovascular events in patients with ACS. However, conflicting results of this combination of ezetimibe and statins were reported. Furthermore, the effectiveness of medications may be affected by combined drug. There are conflicting data regarding to risk of cardiovascular related adverse outcomes in ACS patients who concomitantly used clopidogrel and proton pump inhibitors. The impact of individual PPI on the effectiveness of clopidogrel was not well-explored so far. Objectives The research was divided into four parts. Firstly, the study was designed to examine the percentage of use of medical therapy after hospital discharge for ACS patients. Secondly, the study was designed to assess the impact of dementia on therapy after admission for patients with ACS across different age groups. Thirdly, the study was designed to assess the clinical effectiveness of ezetimibe co-administered with statins in patients after hospitalization for ACS. Lastly, the study was designed to examine the impact of concomitant use of clopidogrel and PPIs on the cardiovascular outcomes of patients with ACS. Furthermore, we sought to quantify the effects of concomitant use of clopidogrel and five individual PPIs. Methods We identified patients who were hospitalized for the first time for ACS between January 1, 2006 and December 31, 2007 (N=111,347) from the NHIRD. Patients with ACS were defined as those who had primary discharge diagnosis codes of 410.xx, 411.xx, or 414.xx based on the 2001 International Classification of Diseases, Ninth Revision, Clinical Modification codes (ICD-9-CM codes). Patients who were previously admitted to hospitals due to ACS in 2005, were less than 18 years old, or had an unknown discharge date for the first ACS event were excluded from our study. The 87,321 persons who met the inclusion/exclusion criteria were identified as original ACS patients. The original ACS patients were further categorized into following: 1. Of 87,321 patients, 1835 patients with dementia and 3670 matched patients without dementia (1:2 ratio, matched by age, gender, and admitted hospital level) were identified from Taiwan's National Health Insurance Research Database. This was a cross sectional study. Use of interventional therapies at hospitalization and medications post-discharge were compared between patients with and without dementia across different age groups (≤65, 66-75, 76-85, >85). Multivariate logistic regression models were performed to examine the impact of dementia on these therapies. 2. Of 87,321 patients, those who were prescribed statins (n=37,753) or ezetimibe plus statins (n=1001) within 365 days after the hospitalization were identified. The propensity score method was further used to identify a 1:1 matched cohort (n=2002). This was a retrospective cohort study. The effect was analyzed by a multivariable Cox proportional hazards regression model. 3. Of 87,321 patients, those who were prescribed clopidogrel (n=37,099) during the followed-up period were identified. Propensity score technique was used to establish a matched cohort in 1:1 ratio (n=5173 for each group). This was a retrospective cohort study. The effect was analyzed by a multivariable Cox proportional hazards regression model. Results The results were divided into four parts as following: 1. Mostly, the proportion of ACS patients receiving medical therapy decreased with age. The proportions of patients receiving aspirin were 24.8% in the oldest age group versus 43.2% in the youngest age group. The proportions of patients receiving medical therapies were higher in male than in female group (31.9%). The proportions of patients receiving aspirin were 45.0% in the male group than 31.9% in the female group. 2. Overall, dementia was associated with a 27% lower likelihood of receipt of interventional therapies (adjusted odds ratio (OR) = 0.73, 95% CI = 0.63-0.83) and a 22% lower likelihood of medical therapies (adjusted OR = 0.78, 0.68-0.89) in ACS patients. The use of interventional and medical therapies decreased with age, and dementia worsened the underutilization. The proportions of patients receiving interventional therapies were 39.4% (without dementia) versus 21.8% (with dementia) in the youngest age group and 18.6 % (without dementia) versus 14.5% (with dementia) in the oldest age group. Similar results were identified in the use of medical therapies in the youngest and oldest age group with or without dementia. 3. The crude event rate of rehospitalization for ACS in the original cohort was 13.4 per 100 person-year (268 events) for the statins plus ezetimibe group, compared with 22.6 per 100 person-year (12,724 events) for the statins alone group (adjusted hazard ratio(HR), 0.69; 95% CI, 0.62-0.78). The crude event rates of rehospitalization due to ACS in the matched cohort were 13.4 and 20.0 per 100 person-year for the statins plus ezetimibe and statins alone group, respectively, (HR, 0.62; 95% CI, 0.53-0.73). Compared to statins alone, the adjusted HRs for rehospitalization for PTCA without stent, with stent, and revascularization for the statins plus ezetimibe group in the matched cohort were 0.61 (95% CI, 0.50-0.75), 0.62 (95% CI, 0.48-0.81), and 0.62 (95% CI, 0.51- 0.76), respectively. 4. The HR of rehospitalization for ACS due to concomitant use of clopidogrel and PPIs group was 1.05 (95% confidence interval, 0.97-1.14, p=0.214) in the propensity score matched cohort. Among all PPIs, only omeprazole was found to be statistically significantly associated with an increased risk of rehospitalization for ACS (adjusted HR, 1.23; 95% CI, 1.07-1.41, p=0.004). Concomitant use of esomeprazole, pantoprazole, rabeprazole, and lansoprazole did not increase the risk. Conclusions The proportions of ACS patients receiving medical and interventional therapies were under 45% and 42%, respectively in Taiwan from our study. The utilization of medical and interventional therapies decreased with age and diagnosis of dementia. Also, our findings suggested that ezetimibe co-administered with statins was related to a significantly lower risk of rehospitalization due to ACS, PTCA, and revascularization than statins alone in Asian ACS patients. However, more studies are required to elucidate the mechanism of clinical outcomes of co-administration of ezetimibe and statins in ACS patients. Finally, our study indicated no statistically significant increase in the risk of rehospitalization for ACS due to concurrent use of clopidogrel and PPIs. Among individual PPIs, only omeprazole was found to be statistically significantly associated with increased risk of rehospitalization for ACS. The mechanism of increased risk of rehospitalization for ACS in combination of clopidogrel and omeprazole require further investigation. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T17:48:22Z (GMT). No. of bitstreams: 1 ntu-101-D96423001-1.pdf: 531023 bytes, checksum: 73598a0d07de4d109fb675da97b63f5a (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | CONTENTS
ACKNOWLEDGEMENTS I 中文摘要II ABSTRACT V CONTENTS VIII LIST OF FIGURES XIII LIST OF TABLES XIV LIST of ABBREVIATIONS XVI LIST of OPERATIONAL DEFINITIONS XVIII Chapter 1 Introduction 1 1.1 Background 1 1.1.1 Overview of Acute Coronary Syndrome (ACS) 1 1.1.2 Age, Dementia, and Therapy After Admission for ACS 2 1.1.3 Impact of Ezetimibe Co-Administered with Statins on Cardiovascular Events Following ACS 3 1.1.4 Cardiovascular Outcomes Associated with Concomitant Use of Clopidogrel and PPIs in Patients with ACS 5 1.2 Objectives 8 Chapter 2 Materials and Methods 10 2.1 Materials 10 2.1.1 National Health Insurance Research Database (NHIRD) 10 2.2 Study Design 11 2.3 Study Population 12 2.3.1 Use of Medical Therapy in Patients with ACS 12 2.3.2 Age, Dementia and Therapy After Admission for ACS 13 2.3.3 Impact of Ezetimibe Co-Administered with Statins on Cardiovascular Events Following ACS 14 2.3.4 Cardiovascular Outcomes Associated with Concomitant Use of Clopidogrel and PPIs in Patients with ACS 17 2.4 Outcome Measurement 18 2.5 Statistical Analysis 19 2.5.1 General Statistical Methods 19 2.5.2 Age, Dementia and Therapy After Admission for ACS 20 2.5.3 Impact of Ezetimibe Co-Administered with Statins on Cardiovascular Events Following ACS 20 2.5.4 Cardiovascular Outcomes Associated with Concomitant Use of Clopidogrel and PPIs in Patients with ACS 21 Chapter 3 Results 24 3.1 Use of Medical Therapy in Patients with ACS 24 3.1.1 Baseline Characteristics 24 3.1.2 Utilization of Medical and Interventional Therapy in Patients with ACS 24 3.2 Age, Dementia, and Therapy After Admission for ACS 25 3.2.1 Baseline Characteristics 25 3.2.2 Association between Dementia and the Use of Interventional and Medical Therapies 26 3.2.3 Subgroup Analysis for Dementia and the Use of Medical Therapies, According to the Definition of Medication Use 28 3.3 Impact of Ezetimibe Co-Administered with Statins on Cardiovascular Events Following ACS 29 3.3.1 Baseline Characteristics 29 3.3.2 Cardiovascular Outcomes Following Acute Coronary Syndrome 30 3.3.3 Subgroup analysis of risk of rehospitalization for ACS by follow-up duration 31 3.4 Cardiovascular Outcomes Associated with Concomitant Use of Clopidogrel and PPIs in Patients with ACS 32 3.4.1 Baseline Characteristics 32 3.4.2 Cardiovascular outcomes after discharge from the hospitalization for ACS 34 3.4.3 Cardiovascular outcomes following acute coronary syndrome based on the use of individual PPI 34 Chapter 4 Discussion 37 4.1 Use of Medical Therapy in Patients with ACS 37 4.2 Age, Dementia and Therapy After Admission for ACS 38 4.3 Impact of Ezetimibe Co-Administered with Statins on Cardiovascular Events Following ACS 42 4.4 Cardiovascular Outcomes Associated with Concomitant Use of Clopidogrel and PPIs in Patients with ACS 48 4.5 The Limitations of the National Health Insurance Research Database and the Strategies 53 Chapter 5 Conclusions 56 REFERENCES 94 APPENDICES 101 | |
dc.language.iso | en | |
dc.title | 急性冠心症病人之藥物治療成效與風險分析 | zh_TW |
dc.title | Effectiveness and Risk of Pharmacotherapy in Patients with Acute Coronary Syndrome | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 林慧玲 | |
dc.contributor.oralexamcommittee | 賴美淑,高純琇,蕭斐元,高雅慧,黃文鴻 | |
dc.subject.keyword | 急性冠心症,老年,老年癡呆症,statin,ezetimibe,clopidogrel,氫離子幫浦抑制劑, | zh_TW |
dc.subject.keyword | acute coronary syndrome,aging,dementia,statin,ezetimibe,clopidogrel,proton pump inhibitor, | en |
dc.relation.page | 110 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-08-14 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 518.58 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。